Cargando…
Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases
GPBAR1, a transmembrane G protein-coupled receptor for bile acids, is widely expressed in multiple tissues in humans and rodents. In recent years, GPBAR1 has been thought to play an important role in bile homeostasis, metabolism and inflammation. This review specifically focuses on the function of G...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793736/ https://www.ncbi.nlm.nih.gov/pubmed/35095513 http://dx.doi.org/10.3389/fphar.2021.805269 |
_version_ | 1784640667674214400 |
---|---|
author | Zhang, Fangling Xiao, Xiaolin Li, Yong Wu, Hefei Deng, Xinyu Jiang, Yinxiao Zhang, Wenwen Wang, Jian Ma, Xiao Zhao, Yanling |
author_facet | Zhang, Fangling Xiao, Xiaolin Li, Yong Wu, Hefei Deng, Xinyu Jiang, Yinxiao Zhang, Wenwen Wang, Jian Ma, Xiao Zhao, Yanling |
author_sort | Zhang, Fangling |
collection | PubMed |
description | GPBAR1, a transmembrane G protein-coupled receptor for bile acids, is widely expressed in multiple tissues in humans and rodents. In recent years, GPBAR1 has been thought to play an important role in bile homeostasis, metabolism and inflammation. This review specifically focuses on the function of GPBAR1 in cholestatic liver disease and summarizes the various pathways through which GPBAR1 acts in cholestatic models. GPBAR1 mainly regulates cholestasis in a holistic system of liver-gallbladder-gut formation. In the state of cholestasis, the activation of GPBAR1 could regulate liver inflammation, induce cholangiocyte regeneration to maintain the integrity of the biliary tree, control the hydrophobicity of the bile acid pool and promote the secretion of bile HCO(3) (−). All these functions of GPBAR1 might be clear ways to protect against cholestatic diseases and liver injury. However, the characteristic of GPBAR1-mediated proliferation increases the risk of proliferation of cholangiocarcinoma in malignant transformed cholangiocytes. This dichotomous function of GPBAR1 limits its use in cholestasis. During disease treatment, simultaneous activation of GPBAR1 and FXR receptors often results in improved outcomes, and this strategy may become a crucial direction in the development of bile acid-activated receptors in the future. |
format | Online Article Text |
id | pubmed-8793736 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87937362022-01-28 Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases Zhang, Fangling Xiao, Xiaolin Li, Yong Wu, Hefei Deng, Xinyu Jiang, Yinxiao Zhang, Wenwen Wang, Jian Ma, Xiao Zhao, Yanling Front Pharmacol Pharmacology GPBAR1, a transmembrane G protein-coupled receptor for bile acids, is widely expressed in multiple tissues in humans and rodents. In recent years, GPBAR1 has been thought to play an important role in bile homeostasis, metabolism and inflammation. This review specifically focuses on the function of GPBAR1 in cholestatic liver disease and summarizes the various pathways through which GPBAR1 acts in cholestatic models. GPBAR1 mainly regulates cholestasis in a holistic system of liver-gallbladder-gut formation. In the state of cholestasis, the activation of GPBAR1 could regulate liver inflammation, induce cholangiocyte regeneration to maintain the integrity of the biliary tree, control the hydrophobicity of the bile acid pool and promote the secretion of bile HCO(3) (−). All these functions of GPBAR1 might be clear ways to protect against cholestatic diseases and liver injury. However, the characteristic of GPBAR1-mediated proliferation increases the risk of proliferation of cholangiocarcinoma in malignant transformed cholangiocytes. This dichotomous function of GPBAR1 limits its use in cholestasis. During disease treatment, simultaneous activation of GPBAR1 and FXR receptors often results in improved outcomes, and this strategy may become a crucial direction in the development of bile acid-activated receptors in the future. Frontiers Media S.A. 2022-01-13 /pmc/articles/PMC8793736/ /pubmed/35095513 http://dx.doi.org/10.3389/fphar.2021.805269 Text en Copyright © 2022 Zhang, Xiao, Li, Wu, Deng, Jiang, Zhang, Wang, Ma and Zhao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Zhang, Fangling Xiao, Xiaolin Li, Yong Wu, Hefei Deng, Xinyu Jiang, Yinxiao Zhang, Wenwen Wang, Jian Ma, Xiao Zhao, Yanling Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases |
title | Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases |
title_full | Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases |
title_fullStr | Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases |
title_full_unstemmed | Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases |
title_short | Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases |
title_sort | therapeutic opportunities of gpbar1 in cholestatic diseases |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793736/ https://www.ncbi.nlm.nih.gov/pubmed/35095513 http://dx.doi.org/10.3389/fphar.2021.805269 |
work_keys_str_mv | AT zhangfangling therapeuticopportunitiesofgpbar1incholestaticdiseases AT xiaoxiaolin therapeuticopportunitiesofgpbar1incholestaticdiseases AT liyong therapeuticopportunitiesofgpbar1incholestaticdiseases AT wuhefei therapeuticopportunitiesofgpbar1incholestaticdiseases AT dengxinyu therapeuticopportunitiesofgpbar1incholestaticdiseases AT jiangyinxiao therapeuticopportunitiesofgpbar1incholestaticdiseases AT zhangwenwen therapeuticopportunitiesofgpbar1incholestaticdiseases AT wangjian therapeuticopportunitiesofgpbar1incholestaticdiseases AT maxiao therapeuticopportunitiesofgpbar1incholestaticdiseases AT zhaoyanling therapeuticopportunitiesofgpbar1incholestaticdiseases |